FridayAug 07, 2026 2:55 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory and commercial milestones amid growing interest in regenerative orthopedic solutions. GelrinC is an off-the-shelf, cell-free implant designed for a streamlined, single-step procedure that supports cartilage regeneration without the cell harvesting and laboratory processing required by some alternative approaches. Regentis is continuing enrollment in its U.S. clinical study, preparing for a potential FDA Premarket Approval submission, expanding commercialization efforts in Europe following CE Mark approval, and optimizing manufacturing for scalability and consistency. To view the full article, visit https://ibn.fm/mVCsB About Regentis Biomaterials Ltd. Regentis Biomaterials is a…

Continue Reading

FridayAug 07, 2026 2:12 pm

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, is developing a two-pronged strategy addressing neurological health through its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. Lucid-MS is designed to target PAD2, an enzyme associated with myelin degradation, with the goal of protecting and potentially restoring the myelin sheath rather than primarily modulating the immune system. The company submitted an IND application to the FDA for a Phase 2 trial and is supporting development through an imaging collaboration…

Continue Reading

FridayAug 07, 2026 1:04 pm

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), two areas that continue to attract significant pharmaceutical investment. A recent article highlights major transactions to illustrate how differentiated antibody-engineering platforms can attract substantial financial commitments even before clinical development reaches advanced stages. VERAXA’s proprietary BiTAC platform supports a pipeline that includes bispecific ADCs, T-cell engagers and engineered antibody formats, potentially creating opportunities for future platform partnerships, licensing agreements or asset-level transactions. To view the full article, visit https://ibn.fm/sMjlp About VERAXA Biotech AG VERAXA is building a premier engine for the discovery and development of…

Continue Reading

FridayAug 07, 2026 10:37 am

QualityStocksNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Featured in AINewsWire Editorial on AI Compute Infrastructure 

AZIO AI Holdings (NASDAQ: AZIO) announced its inclusion in an AINewsWire ("AINW") editorial examining the growing shortage of AI compute infrastructure and its implications for the next phase of artificial intelligence adoption. The editorial, titled "The Compute Shortage Threatening AI's Next Growth Phase," highlights industry forecasts calling for an estimated $6.7 trillion in AI-related data center investment by 2030 and discusses AZIO's strategy to address increasing demand for AI compute capacity. The editorial also spotlights AZIO's recently announced agreement with Power Champion Investment Limited for the purchase of up to 128 NVIDIA(TM) B300 GPU systems, positioning the company as an emerging provider of AI infrastructure. The editorial notes that the…

Continue Reading

FridayAug 07, 2026 9:20 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports 57% Increase in Fiscal First-Quarter Net Income

Earth Science Tech (OTC: ETST) reported fiscal first-quarter 2027 results highlighted by a 57% year-over-year increase in net income to $715,697 on revenue of $9.0 million, up 3% from the prior-year period. Gross profit rose to $6.3 million, operating cash flow more than doubled to $707,131 and total assets increased to $10.4 million. Diluted earnings per share improved to $0.003 from $0.001, while the company repurchased and retired more than 3.7 million common shares during the quarter without adding debt. The company said all key operating subsidiaries remained profitable as it continued expanding the licensing footprint of its compounding pharmacy…

Continue Reading

FridayAug 07, 2026 9:00 am

QualityStocksNewsBreaks – Wrap Technologies, Inc. (NASDAQ: WRAP) Launches WrapTactics LMS, Completing WrapShield Training Foundation

Wrap Technologies (NASDAQ: WRAP) announced the commercial launch of WrapTactics(TM) Learning Management System ("LMS"), completing the training foundation of its WrapShield(TM) six-tier human-centered response architecture. The platform provides digital learning, certification management, immersive virtual reality training, compliance reporting and mobile learning to support deployment of the company's non-lethal response technologies, including BolaWrap(R) 150. The launch follows the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives' 2026 classification of BolaWrap 150 as an instrument of restraint rather than a firearm or weapon, a determination the company said expands procurement opportunities beyond traditional law enforcement markets. Wrap said WrapTactics is designed to create…

Continue Reading

ThursdayAug 06, 2026 2:06 pm

QualityStocksNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Featured in AINewsWire Editorial on Growing AI Infrastructure Opportunity

AZIO AI Holdings (NASDAQ: AZIO) is featured in a new AINewsWire editorial examining how surging demand for artificial intelligence infrastructure is creating opportunities for companies building the physical foundation needed to support AI deployment. The editorial highlights the company's recent agreement with Power Champion Investment Limited covering the purchase of up to 128 NVIDIA(TM) HGX B300 GPU systems, representing an estimated hardware value of approximately $77 million if fully executed, and notes that the agreement builds on an earlier hosting relationship while reflecting AZIO's integrated AI infrastructure strategy. The editorial also reviews AZIO's transformation into a dedicated AI infrastructure company focused on GPU compute,…

Continue Reading

ThursdayAug 06, 2026 12:59 pm

QualityStocksNewsBreaks – American Fusion Inc. (OTC: AMFN) Expands Patent Portfolio, Advances Texatron Fusion Development

American Fusion (OTC: AMFN) announced the filing of six additional U.S. patent applications covering multiple aspects of its proprietary Texatron(TM) Fusion Engine(TM), increasing its intellectual property portfolio to 82 U.S. patent applications. The new filings span reactor architecture, plasma confinement, electromagnetic systems and related technologies that support the ongoing development and future commercialization of the Texatron platform. The company said the expanded portfolio reflects its strategy of protecting innovations across the fusion engine's core technologies. American Fusion also provided updates on several corporate and engineering initiatives, including its response to what it believes are the final comments on its Form 211 application, the last regulatory step before potential eligibility…

Continue Reading

ThursdayAug 06, 2026 12:44 pm

QualityStocksNewsBreaks – Perpetuals.com Ltd. (NASDAQ: PDC) Reports Strong Backtest Results for BayesShield AI Trading Engine

Perpetuals.com (NASDAQ: PDC) announced backtest results for version two of its patent-pending BayesShield artificial intelligence engine, which powers its UpsideOnly paper trading platform. Using the same production code deployed on the live platform, the company replayed approximately 1.07 billion historical order fills over a 375-day period, generating a hypothetical non-compounded return of 380% with a maximum drawdown of 27% and a return-to-drawdown ratio of 4.4. Starting with $400,000 in simulated capital, the strategy produced hypothetical profits of $1.522 million, ending the test period with $1.922 million. The company said the AI model identifies consistently successful traders and generates automated trading signals when qualified users independently take similar positions at roughly the same time,…

Continue Reading

ThursdayAug 06, 2026 10:20 am

QualityStocksNewsBreaks – NANO-X IMAGING LTD (NASDAQ: NNOX) Announces $8 Million Registered Direct Offering

NANO-X IMAGING (NASDAQ: NNOX) announced a securities purchase agreement with a single long-term institutional investor for a registered direct offering expected to generate approximately $8 million in gross proceeds before fees and expenses. The financing includes the sale of 8 million ordinary shares, or prefunded warrants in lieu thereof, together with warrants to purchase up to an additional 8 million ordinary shares at a combined purchase price of $1.00 per share and accompanying warrant. The warrants will carry a $1.15 exercise price, become exercisable six months after issuance and expire five years after closing. The offering is expected to close…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered